The first‐line treatment in SCLC recommended by the United States and Europe is 4‐6 cycles of etoposide plus cisplatin or carboplatin and the FDA has approved the PD‐L1 inhibitor atezolizumab in combination with carboplatin and etoposide as a first‐line therapy for SCLC (19). Here, CD274 is linked to small cell lung carcinoma.